Effect Of Rilapladib (SB-659032) On Platelet Aggregation

Phase 1

Completed

• Conditions: Atherosclerosis; Healthy Subjects

• Registration Number: NCT00387257
• Lead Sponsor: GlaxoSmithKline

Brief Summary

The purpose of this study is to compare the effects of repeat doses of SB-659032 with placebo on platelet aggregation in subjects.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-10
• Study First Submitted: 2006-10-10
• Study First Submitted QC: 2006-10-10
• Study First Posted: 2006-10-12
• Primary Completion: 2007-04
• Study Completion: 2007-04
• Status Verified: 2015-04
• Last Update Submitted: 2015-04-14
• Last Update Posted: 2015-04-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 58

Inclusion Criteria

• Subjects with QTc < 450 msec as measured at screening.

Read More

Exclusion Criteria

• History of asthma.
• Smokers.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Collagen EC50 values on Day 35 (or 21 days post last dose) as determine by optical aggregometry.	on Day 35 (or 21 days post last dose) as determine by optical aggregometry

Secondary Outcome Measures

Name	Time	Method
Collagen EC50 values on Day 1 and Day 14 as determined by optical aggregometry Plasma Lp-PLA2 activity Clinical safety data Concentrations of rilapladib and SB-664601.	on Day 1 and Day 14 as determined by optical aggregometry

Trial Locations

Locations (1)

GSK Investigational Site; 🇦🇺 Randwick, New South Wales, Australia